why choose us

First received: June 02, 2023

Clinical Trial: Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: AL Amyloidosis

Study Type: INTERVENTIONAL


Official Title: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)

Brief Summary: The purpose of this study is to determine the event-free survival (EFS) after 3-6 versus 18 cycles of daratumumab maintenance following 6 cycles induction of daratumumab-CyBorD in newly diagnosed AL amyloidosis.

Read more